OCENLO
LIVE

Serial Number

98229386

Owner

Bristol-Myers Squibb Company

Attorney

Xiomara Triana

Filing Date

Oct 18, 2023

Add to watchlist:

No watchlists yet
View on USPTO

OCENLO Trademark

Serial Number: 98229386

OCENLO is a trademark filed by Bristol-Myers Squibb Company on October 18, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

October 18, 2023

Registration Date

Not Registered

Published for Opposition

August 6, 2024

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations; diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use.

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 25, 2026 EXRA
SOU EXTENSION 3 GRANTED
Mar 24, 2026 EX3G
SOU EXTENSION 3 FILED
Mar 24, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 24, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 25, 2025 EXRA
SOU EXTENSION 2 GRANTED
Sep 24, 2025 EX2G
SOU EXTENSION 2 FILED
Sep 24, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 1, 2025 EXRA
SOU EXTENSION 1 GRANTED
Apr 1, 2025 EX1G
SOU EXTENSION 1 FILED
Apr 1, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 1, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 1, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 6, 2024 NPUB
PUBLISHED FOR OPPOSITION
Aug 6, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 17, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 29, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 26, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 26, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 26, 2024 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Jun 11, 2024 GPRN
PRIORITY ACTION E-MAILED
Jun 11, 2024 GPRA
PRIORITY ACTION WRITTEN
Jun 11, 2024 CPRA
ASSIGNED TO EXAMINER
May 30, 2024 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 23, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 23, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 23, 2024 COAR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 24, 2023 NWOS
NEW APPLICATION ENTERED
Oct 21, 2023 NWAP